SOURCE: BioMedReports


August 23, 2011 10:10 ET

Trade Catalyst Report: Disruptive Technology With Multiple Market Applications Up for FDA Approval

LOS ANGELES, CA--(Marketwire - Aug 23, 2011) - SANUWAVE Health (OTCBB: SNWV) is suddenly positioned to become one of the leaders in the emerging field of regenerative medicine -- not by harvesting or employing stem cells or creating living tissues, but by using a highly effective, non-invasive medical device which has been perfected to activate a biological response for the repair and regeneration of tissue, musculoskeletal and vascular structures.

The firm's patented medical device technologies are set to address multiple large healthcare markets, exceeding $10 billion in total.

SANUWAVE recently submitted to the U.S. Food and Drug Administration (FDA) the final module of its Premarket Approval (PMA) application for their dermaPACE® device for the treatment of diabetic foot ulcers (DFU).

SANUWAVE's management plan calls for the company to go after multiple, large U.S. markets, exceeding $10 billion in total with this technology starting with patients experiencing chronic wounds.

The latest figures indicate that 27 million people in the U.S. have diabetes and that 79 million are pre-diabetic. That members of that group report having in excess of 1.5 million diabetic ulcers annually and that 25% of diabetics will acquire a non-healing ulcer in their lifetime are compelling figures that foreshadow just how important this treatment technology might become given that this health problem is rising significantly as the U.S. population ages.

If and when approved, this will be the first device-based therapy with a PMA approval. According to analysts, even a 4 - 5% market share gain could yield revenues north of $80 million over the next 5 years.

The full trade catalyst report on this innovative technology and what it means for investors is available now at:

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com.

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556